TRUST Study: Participation in Randomized Controlled Trials and Subsequent Adherence to Visiting Medical Institutions and Taking Medications in Patients with Cardiovascular Diseases. Part I. Motives for the Patients' Participation in Clinical Trials

Aim. To describe the design of TRUST study (Influence of Participation in Randomized Controlled Trials on adheRence to Medicines' Intake and regUlar viSits to the docTor) and present the first part of this study to determine the motives of patient participation in clinical trials.

Material and methods. The main group of TRUST study included patients of the outpatient registrar PROFILE, which were taking part in one or more international randomized clinical trials, conducted from 2011 to 2018. The standard registration card of PROFILE register was used to assess the clinical and demographic data of patients.

In 2019 full-time/telephone contact with patients was established, during which, based on the original questionnaire, the motives of the participation in trials, their attitude towards randomized controlled trials (RCT), and their adherence to monitoring in medical institutions were determined. This publication presents the results of the first part of the study.

Results. 102 patients were enrolled in the study, telephone /personal contact was established for 88 patients, the life status of 9 of them by 2019 was defined as "dead", 77 were interviewed, 2 – refused to answer. Over 80% of patients completed participation in RCTs more than one year ago. 71.6% of patients participated in more than one RCT. In 60% of cases, patients claimed that this was the proposal of the doctor of the scientific center. For 79% of patients, RCTs had the opportunity to access highly skilled medical care. Only 18% of patients indicated that they received the necessary qualified medical care before entering the study. In cases where patients answered dichotomous questions (such as "yes"/"no"), the overwhelming majority of patients (74%) claimed that it was the authority of the doctor of the scientific center and the fear of losing the possibility of further observation became the main reason for participating in RCTs.

Conclusion. In the first part of the TRUST study, it was revealed that in Russia the main reason of participation in RCT is the recommendation of a doctor from a specialized scientific center.

1. The pharmaceutical industry and global health: facts and figures 2014. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) [cited by Aug 01, 2019]. Available from: http://www.ifpma.org/fileadmin/content/Publication/2014/IFPMA_Facts_And_Figures_2014.pdf.

2. Martsevich S.Y., Kutishenko N.P. Randomised Clinical Trials and Observational Studies: the Ratio in the Hierarchy of Evidence of the Efficacy of Drugs. Rational Pharmacotherapy in Cardiology. 2016;12(5):567-73 (In Russ) [Марцевич С.Ю., Кутишенко Н.П. Рандомизированные клинические исследования и наблюдательные исследования: соотношение в иерархии доказательств эффективности лекарств. Рациональная Фармакотерапия в Кардиологии. 2016;12(5):567-73]. DOI:10.20996/1819-6446-2016-12-5-567-573.

3. Blaschke T.F, Osterberg L., Vrijens B., Urquhart J. Adherence to medications. Insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2012;52:275-301. DOI:10.1146/annurev-pharmtox-011711-113247.

4. Warren S.R., Raisch D.W., Campbell H.M., Guarino P.D. et al. Medication adherence assessment in a clinical trial with centralized follow-up and direct-to-patient drug shipments. Clinical Trials. 2011;10(3):441-8. DOI:10.1177/1740774511410331.

5. CONSORT 2010 Explanation and elaboration: updated guidelines for reporting parallel group randomized trials. BMJ. 2011;343:d6131. DOI:10.1136/bmj.d6131.

6. Martsevich S.Y., Gaysenok O.V., Tripkosh S.G., et al. Medical supervision in specialized center and the quality of lipid-lowering therapy in patients with cardiovascular diseases (according to the PROFILE register). Rational Pharmacotherapy in Cardiology. 2013;9(2):133-137 (In Russ.). DOI:10.20996/1819-6446-2013-9-2-133-137.

7. Martsevich S.Y., Lukina Y.V., Kutishenko N.P., et al. Adherence to statins therapy of high and very high cardiovascular risk patients in real clinical practice: diagnostics and possible ways to solve the problem (According to the PRIORITY observational study). Rational Pharmacotherapy in Cardiology. 2018;14(6):891-900 (In Russ.). DOI:10.20996/1819-6446-2018-14-6-891900.

8. World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310(20):2191-4. DOI:10.1001/jama. 2013.281053.

9. Guidelines for good clinical practice (GCP) for trials on pharmaceutical products. WHO Technical Report Series, No. 850 1995, Annex 3. [cited by Aug 01, 2019]. Available from: https://apps.who.int/medicinedocs/pdf/whozip13e/whozip13e.pdf.

10. Nappo S.A., Iafrate G.B., Sanchez Z.M. Motives for participating in a clinical research trial: a pilot study in Brazil. BMC Public Health. 2013;13-19. DOI:10.1186/1471-2458-13-19.

11. Soule M.C., Beale E.E., Suarez L., Beach S.R.б et al. Understanding motivations to participate in an observational research study: Why do patients enroll? Social Work in Health Care. 2016;55(3):23146. DOI:10.1080/00981389.2015.1114064.

12. Martin S.S., Ou F.S., Newby L.K., Sutton V., et al. Patientand trial-specific barriers to participation in cardiovascular randomized clinical trials. J Am Coll Cardiol. 2013;61(7):762-9. DOI:10.1016/j.jacc.2012.10.046.

13. Kasner S.E., Del Giudice A., Rosenberg S., et al. Who will participate in acute stroke trials? Neurology. 2009;72(19):1682-8. DOI:10.1212/WNL.0b013e3181a55fbe.

14. McMahon V.A., Matthews S., Capper H., et al. Understanding decision and enabling factors influencing clinical trial participation in Australia: a view point. Asian Pac J Cancer Prev. 2011;12(11):3153-6.

15. Walsh E., Sheridan A. Factors affecting patient participation in clinical trials in Ireland: A narrative review. Contemporary Clinical Trials Communications. 2016;3:23-31. DOI:10.1016/j.conctc. 2016.01.002.

16. Russian statistical annual. Statistical bulletin. Moscow: Rosstat; 2018 (In Russ.).

17. Zvonareva O., Engel N., Martsevich S., et al. International clinical trials, cardiovascular disease and treatment options in the Russian Federation: Research and treatment in practice. Social Science & Medicine. 2015;128:255-62. DOI:10.1016/j.socscimed.2015.01.038.

18. Gray S.W., Hlubocky F.J., Ratain M.J., Daugherty C.K. Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials. J Clin Oncol. 2007;25(23):3488-94. DOI:10.1200/JCO.2007.11.7283.

19. Gheorghiade M., Vaduganathan M., Greene S.J., et al. Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Fail Rev. 2014;19(2):135-52. DOI:10.1007/s10741-012-9361-8.